Valoctocogene roxaparvovec is a Gene Therapy owned by BioMarin Pharmaceutical, and is involved in 9 clinical trials, of which 3 were completed, and 6 are ongoing.
Valoctocogene roxaparvovec (BMN-270) expresses the gene which stimulates the production of clotting protein Factor VIII and replace the mutant genes. Thus the drug candidate restores the factor VIII plasma concentrations to levels which is adequate for normal clotting in hemophilia A.
The revenue for Valoctocogene roxaparvovec is expected to reach a total of $21.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Valoctocogene roxaparvovec NPV Report.
Valoctocogene roxaparvovec Overview
Valoctocogene Roxaparvovec (Roctavian) is a gene therapy medicinal product that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). It is formulated as a solution for infusion for intravenous route of administration. It is indicated for the treatment of severe hemophilia A (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).
Valoctocogene roxaparvovec (BMN-270) is under development for treatment of hemophilia A. It is administered as an intravenous infusion. The drug candidate is a recombinant adeno-associated virus (AAV) 5 coding for human-coagulation factor VIII.
BioMarin Pharmaceutical Overview
BioMarin Pharmaceutical (BioMarin) develops and commercializes innovative medicines for the treatment of rare genetic diseases and medical conditions such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. The company focuses on developing breakthrough treatments for debilitating and life-threatening diseases. Its product category consists of multiple clinical and preclinical offerings which include Naglazyme-Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme-MPS I and others. The company operates through its manufacturing facilities in Novato, California. It conducts business operations in the US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.
The company reported revenues of (US Dollars) US$1,846.3 million for the fiscal year ended December 2021 (FY2021), a decrease of 0.8% over FY2020. The operating loss of the company was US$82.3 million in FY2021, compared to an operating loss of US$36.8 million in FY2020. The net loss of the company was US$64.1 million in FY2021, compared to a net profit of US$859.1 million in FY2020. The company reported revenues of US$505.3 million for the third quarter ended September 2022, a decrease of 5.3% over the previous quarter.
Quick View – Valoctocogene roxaparvovec
|Highest Development Stage|